Stimwave Technologies Announces Chris Valois as Chief Marketing and Strategy Officer

“We are pleased to have Chris join our team in this newly created critical function. His leadership experience with new therapy development, strategic planning, and commercial roles will be invaluable to our company’s growth trajectory. This is a key turning point in the continued commercialization of our innovative spinal cord and peripheral nerve stimulation platforms,” said Aure Bruneau, Chief Executive Officer. “With many of the foundational pieces of our organization in place, we are now prepared to further accelerate our collaboration with medical facilities, physicians and their teams to bring our therapy to many more patients in need of freedom from their chronic pain. We’re confident that Chris will help propel Stimwave Technologies to the next level.”

Mr. Valois brings over two decades of leadership expertise in the medical technology industry to the company, including extensive experience in product management, marketing, and brand management. Importantly, he has significant experience with both neuromodulation technologies as well as minimally invasive solutions for spine and orthopedic extremities. Most recently, he served as the General Manager of the US subsidiary of FH Ortho, which was recently acquired by Olympus. During his time there, Mr. Valois managed all areas of the US operations, while emphasizing cross-functional collaboration, product launch, and commercial excellence, with demonstrated, sustained business growth. Chris also served as the Vice President of Sales and Marketing at Xtant Medical where he led commercial operations and developed strategic initiatives for this orthobiologics company. Prior to that, Mr. Valois held various roles of increasing responsibilities at Tornier, which was then acquired by Wright Medical/Stryker, where he continued to work to develop a long-term strategic plan and form a marketing team for their growing portfolio. In addition, Mr. Valois served in leadership positions at Zimmer Biomet, St. Jude Medical, and Medtronic after beginning his career as an engineer. Mr. Valois holds a Bachelor of Science degree from the University of Wisconsin and a Master of Business Administration from the University of St. Thomas.

“I am very excited to be joining the Stimwave Technologies team at this critical inflection point in our growth,” said Mr. Valois. “With industry-leading technology, market leading physician collaboration, strong clinical evidence, and a compelling product pipeline, our Freedom therapies will positively evolve the way chronic pain is managed and benefit many patients globally.”

Upcoming Industry Conference Participation
Stimwave Technologies will be participating in multiple upcoming industry conferences.
American Society of Pain and Neurosciences (ASPN) Advanced Lab and Data Reveal
January 7-8, 2022
Las Vegas, Nevada
Table #2 (Lab) Table #18 (data reveal)

North American Neuromodulation Society (NANS) 2022 Annual Meeting
January 13-15, 2022
Orlando, Florida
Booth #704

About Stimwave Technologies, Inc.

Stimwave Technologies is a medical device company that develops, manufactures and markets, neuromodulation products. Its Peripheral Nerve Stimulation (PNS) and Spinal Cord Stimulation (SCS) products are implanted technology that block pain signals to the brain and provide a drug-free alternative for treating patients suffering from chronic pain. Stimwave Technologies’ Freedom Systems, the SCS and PNS products, provide a unique and innovative technology with an HF-EMC wireless energy transfer from an external transmitter and antenna to the implanted electrode array and separate receiver. Stimwave Technologies’ FDA-cleared product portfolio can treat nerves from the neck down that are causing pain. Stimwave Technologies’ principal place of business is in Pompano Beach, Florida and it operates worldwide through its operating subsidiaries. For more information, please visit https://stimwavefreedom.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005119/en/